Abstract

Objective: Pseudomonas aeruginosa is among the most common nosocomial opportunistic pathogens capable of acquiring multi-drug resistance. Recent data on antibiotic resistance in Northern Cyprus is limited. We aimed evaluate antibiotic susceptibility profiles of P. aeruginosa strains isolated from clinical samples and contribute to the update of antibiotic use policies in the country.

Methods: Total of 504 P. aeruginosa strains sent to Microbiology Laboratory from various clinics from September 2016 to October 2019 were retrospectively analyzed. Clinical samples were cultured on %5 sheep blood agar and eosin-methylene blue agar. BD Phoenix™ 100 (Becton Dickinson Co., Sparks, Maryland, USA) automated bacterial identification system and conventional antimicrobial susceptibility testing was used. Antimicrobial susceptibility was determined in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. The distribution of P. aeruginosa isolates according to hospital services, sample types, admission types, age group, and antibiotic resistance rates were investigated.

Results: P. aeruginosa was mostly isolated from urine (37.3%), deep tracheal aspirate (17.9%) and abscess/wound material (17.9%) samples. Strains were most commonly obtained from the intensive care clinics (35.9%). Infections were observed mainly in >65 age group (49.6%) and in-patients (70.8%) group. Antibiotic resistance rates were detected as 47.7% for aztreonam, 32% for cefepime, 26.3% for ceftazidime, 26.4% for imipenem, 25.6% for ciprofloxacin, 24.6% for meropenem, 19.7% for piperacillin-tazobactam, 13.5% for gentamicin, 12.2% for colistin and 5.3% for amikacin. Multi-drug resistant P. aeruginosa rate was 19.2%. When compared with 2010-2014, a substantial increase in rates of cefepime, ceftazidime, ciprofloxacin, piperacillin-tazobactam and carbapenem resistance was detected within the last three years.

Conclusions: In this study, the highest resistance rates were detected against aztreonam and cefepime, and the highest susceptibility was observed for colistin and amikacin. These results may be used for empirical treatments, establishment of rational antibiotic use policies and prevention of emerging antibiotic resistance problem in Cyprus.

Volume 37, Issue 1 Volume 36, Issue 4 Volume 36, Supplement 1 Volume 36, Issue 3 Volume 36, Issue 2 Volume 36, Issue 1 Volume 35, Issue 4 Volume 35, Issue 3 Volume 35, Issue 2 Volume 35, Issue 1 Volume 34, Issue 3 Volume 34, Issue 2 Volume 34, Issue 1 Volume 33, Issue 3 Volume 33, Issue 2 Volume 33, Issue 1 Volume 32, Issue 3 Volume 32, Supplement 1 Volume 32, Supplement 2 Volume 32, Issue 2 Volume 32, Issue 1 Volume 31, Issue 3 Volume 31, Issue 2 Volume 31, Supplement 1 Volume 31, Issue 1 Volume 30, Issue 3 Volume 30, Issue 2 Volume 30, Supplement 1 Volume 30, Issue 1 Volume 29, Issue 3 Volume 29, Issue 2 Volume 29, Issue 1 Volume 28, Supplement 1 Volume 28, Issue 3 Volume 28, Issue 2 Volume 28, Issue 1 Volume 27, Supplement 1 Volume 27, Issue 3 Volume 27, Issue 2 Volume 27, Issue 1 Volume 26, Issue 3 Volume 26, Supplement 1 Volume 26, Issue 2 Volume 26, Issue 1 Volume 25, Issue 3 Volume 25, Issue 2 Volume 25, Issue 1 Volume 24, Issue 3 Volume 24, Issue 2 Volume 24, Issue 1 Volume 23, Issue 3 Volume 23, Issue 2 Volume 23, Issue 1 Volume 22, Issue 3 Volume 22, Issue 2 Volume 22, Issue 1 Volume 21, Issue 3 Volume 21, Supplement 2 Volume 21, Supplement 1 Volume 21, Issue 2 Volume 21, Issue 1 Volume 20, Issue 3 Volume 20, Supplement 2 Volume 20, Issue 2 Volume 20, Issue 1 Volume 20, Supplement 1 Volume 19, Issue 3 Volume 19, Issue 2 Volume 19, Issue 1 Volume 18, Issue 3 Volume 18, Supplement 1 Volume 18, Issue 2 Volume 18, Issue 1 Volume 17, Issue 3 Volume 17, Issue 2 Volume 17, Issue 1 Volume 16, Issue 3 Volume 16, Issue 2 Volume 16, Issue 1 Volume 1, Supplement 1 Volume 15, Issue 3 Volume 15, Issue 2 Volume 15, Issue 1 Volume 14, Issue 3 Volume 14, Issue 2 Volume 14, Issue 1 Volume 13, Issue 3 Volume 13, Issue 2 Volume 13, Supplement 1 Volume 13, Issue 1 Volume 12, Issue 3 Volume 12, Issue 2 Volume 12, Issue 1 Volume 11, Issue 3 Volume 11, Issue 2 Volume 11, Supplement 1 Volume 11, Issue 1 Volume 10, Issue 3 Volume 10, Issue 2 Volume 10, Issue 1 Volume 9, Issue 3 Volume 9, Issue 2 Volume 9, Issue 1 Volume 8, Issue 3 Volume 8, Issue 2 Volume 8, Issue 1 Volume 6, Issue 3 Volume 7, Issue 1 Volume 7, Issue 2 Volume 7, Issue 3 Volume 4, Issue 3 Volume 5, Issue 1 Volume 5, Issue 2 Volume 5, Issue 3 Volume 6, Issue 1 Volume 6, Issue 2 Volume 3, Issue 1 Volume 3, Issue 2 Volume 3, Issue 3 Volume 4, Issue 1 Volume 4, Issue 2 Volume 1, Issue 2 Volume 2, Issue 1 Volume 2, Issue 2 Volume 2, Issue 3 Volume 1, Issue 1